JAMA Study Finds Blood Test May Predict Alzheimer's Risk Years Ahead
Researchers reported in JAMA on July 15, 2026, that baseline plasma p-tau217 levels in symptom-free older adults strongly predicted Alzheimer's-type cognitive decline years before symptoms.[1]
Among 2,684 cognitively normal participants enrolled since 2004, those with very high p-tau217 faced a 38% risk of impairment at five years and 78% at ten years.[1] Study authors and outside commentators cautioned the blood test is not yet accurate enough to give individual prognoses but said it could immediately help enroll high-risk people into prevention and treatment trials.[1]
In 2020, a Lund University team showed plasma p-tau217 could distinguish Alzheimer's pathology from other brain diseases. A 2025 prognostic analysis found p-tau217 levels in symptom-free adults forecasted progression to mild cognitive impairment over several years. In April 2026, investigators at Mass General Brigham linked rising p-tau217 to faster amyloid buildup on PET scans before scans became abnormal.
Blood-based tests have shown very high accuracy for detecting amyloid in some studies, but editors say more validation is needed before clinical use for individuals. About 7.4 million Americans age 65 and older are living with Alzheimer's in 2026, and researchers say better blood screening could speed recruitment for trials that currently need far more volunteers. As of 2024, 164 Alzheimer's trials required an estimated 51,000 participants to fill them, while only about 11,000 enroll each year.
The mainstream summary emphasizes the predictive capability of p-tau217 levels for Alzheimer's cognitive decline but does not mention the significant accuracy of these blood tests in detecting amyloid positivity, which is reported to be as high as 0.95-0.97 in some studies, nearly matching PET imaging results. This detail, highlighted by @siimland, suggests that the potential for blood-based biomarkers in clinical settings may be more advanced than the summary indicates. Furthermore, while the mainstream account notes the need for further validation, it overlooks the editorial commentary from @JAMA_current, which stresses that higher p-tau217 levels correlate with a greater absolute risk of cognitive impairment, underscoring the urgency for clinical application in identifying at-risk individuals.
Additionally, the summary does not address the broader implications of rising Alzheimer's prevalence, projected to increase from 7.4 million to 13.8 million Americans aged 65 and older by 2060, as noted in the Alzheimer's Association report. This demographic shift highlights the pressing need for effective screening methods, such as the p-tau217 test, to facilitate recruitment for the 164 ongoing clinical trials that currently face significant enrollment challenges. As of 2024, only 11,000 participants enroll annually, far short of the estimated 51,000 needed, a fact that emphasizes the potential impact of improved blood screening on trial participation.[2][3]
Show source details & analysis (1 source)
📊 Relevant Data
An estimated 7.4 million Americans age 65 and older are living with Alzheimer's disease in 2026, representing about 1 in 9 people in that age group.
Alzheimer's Disease Facts and Figures — Alzheimer's Association
As of 2024, an estimated 51,000 participants were needed to fully enroll the 164 Alzheimer's clinical trials in the pipeline, while only about 11,000 enroll annually.
Advancing the science of recruitment for Alzheimer's clinical trials — PMC / NIH
📌 Key Facts
- On July 15, 2026, researchers reported in JAMA that baseline p-tau217 blood levels in symptom-free older adults were strongly associated with later Alzheimer’s-type cognitive decline.
- Among 2,684 cognitively normal participants enrolled since 2004, those with very high p-tau217 had a 38% risk of impairment at five years and 78% at ten years, while very low levels signaled low risk.
- Study authors and outside commentators said the test is not yet accurate enough for individual prognoses but could immediately help enroll high-risk participants into prevention and treatment trials.
📰 Source Timeline (1)
Follow how coverage of this story developed over time